Casdin Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Casdin Capital’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000,000	Closed	-$4.14M	–	43
2022 Q2	$4.14M	Buy	+1,000,000	New	+$4.32M	0.35%	32
2021 Q3	–	Sell	-550,000	Closed	-$6.58M	–	58
2021 Q2	$6.58M	Hold	550,000	–	–	0.17%	47
2021 Q1	$6.89M	Sell	550,000 -530,000	-49%	-$7.14M	0.21%	43
2020 Q4	$16.9M	Hold	1,080,000	–	–	0.5%	38
2020 Q3	$10.2M	Sell	1,080,000 -375,000	-26%	-$4.06M	0.46%	35
2020 Q2	$13M	Hold	1,455,000	–	–	0.77%	30
2020 Q1	$9.27M	Hold	1,455,000	–	–	0.98%	31
2019 Q4	$12.2M	Hold	1,455,000	–	–	1.12%	27
2019 Q3	$13.2M	Sell	1,455,000 -75,000	-5%	-$841K	1.36%	23
2019 Q2	$16.5M	Buy	1,530,000 +450,000	+42%	+$4.79M	1.54%	21
2019 Q1	$10.3M	Hold	1,080,000	–	–	1.13%	22
2018 Q4	$12.4M	Sell	1,080,000 -920,000	-46%	-$11.4M	2.12%	19
2018 Q3	$33.9M	Buy	2,000,000 +600,000	+43%	+$9.12M	4.12%	12
2018 Q2	$19.9M	Hold	1,400,000	–	–	2.78%	17
2018 Q1	$26.6M	Hold	1,400,000	–	–	4.68%	10
2017 Q4	$23M	Hold	1,400,000	–	–	5.59%	8
2017 Q3	$21M	Hold	1,400,000	–	–	5.93%	4
2017 Q2	$12.3M	Buy	1,400,000 +550,000	+65%	+$3.53M	4.56%	7
2017 Q1	$4.42M	Buy	+850,000	New	+$3.41M	2.61%	12

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Casdin Capital's SGMO Position: Q3 2022 in Review

Casdin Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2022, closing a stake of 1,000,000 shares — an estimated $4.14M sold.

Casdin Capital first reported a position in SGMO in Q1 2017 and held it in 19 quarters. The position peaked at $33.9M in Q3 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q3 2022.

Casdin Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
Casdin Capital sold 1,000,000 SANGAMO THERAPEUTICS INC shares in Q3 2022, an estimated $4.14M.
Casdin Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2017 and held it in 19 quarters.
Casdin Capital's SANGAMO THERAPEUTICS INC position peaked at $33.9M in Q3 2018.
197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2022.

Based on Casdin Capital's 13F filing for Q3 2022, filed 14 Nov 2022.